{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:08:20Z","timestamp":1776100100734,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Ixekizumab, an IL\u201017A monoclonal antibody, is administered in Japan as 160\u2009mg initially, then 80\u2009mg every 2\u2009weeks (Q2W) through Week 12 and every 4\u2009weeks thereafter. Continued Q2W dosing is allowed if response is insufficient at Week 12. This study evaluated long\u2010term effectiveness and factors associated with sustained Q2W dosing in real\u2010world practice. Data from the Western Japan Psoriasis Registry were analyzed for patients treated &gt;\u20091\u2009year. Outcomes included achievement of body surface area (BSA) \u2264\u20093% and physician global assessment (PGA) 0\/1. Logistic regression adjusted for age, sex, and psoriatic arthritis identified predictors of Q2W maintenance. Among 114 patients (35 for 1\u2009year, 79 for &gt;\u20091\u2009year; mean duration 35\u2009months), BSA \u2264\u20093% was achieved by 88.6% and 79.7%, and PGA 0\/1 by 82.9% and 75.9%, respectively. Q2W dosing continued in 44 patients (38.6%). Higher body mass index (OR 1.11, 95% CI 1.01\u20131.23) and prior biologic therapy (OR 2.37, 95% CI 1.01\u20135.58) were significant predictors; smoking, alcohol, baseline severity, and nail involvement were not. Ixekizumab showed durable effectiveness, and sustained Q2W dosing was a practical option for patients with higher BMI or prior biologic exposure.<\/jats:p>","DOI":"10.1111\/1346-8138.70142","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:56:32Z","timestamp":1767614192000},"page":"640-644","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Continuous 2\u2010Week Dosing of Ixekizumab in Practice: A Multicenter Study"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-9205","authenticated-orcid":false,"given":"Noriko","family":"Tsuruta","sequence":"first","affiliation":[{"name":"Department of Dermatology Faculty of Medicine, Fukuoka University  Fukuoka Japan"},{"name":"Division of Dermatology Kitakyushu Yahata Hospital  Fukuoka Japan"},{"name":"Western Japan Inflammatory Skin Disease Research Group  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine, Fukuoka University  Fukuoka Japan"},{"name":"Western Japan Inflammatory Skin Disease Research Group  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-2014","authenticated-orcid":false,"given":"Hisatomi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health Faculty of Medicine, Fukuoka University  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"K.K ELJ \u201cTaltz [Package Insert] \u201d Kobe Japan (2024)."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16092"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14808"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1473551"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14066"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1755009"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15288"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.06.004"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00490-2"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00722-y"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16737"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1746734"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.621"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16426"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18550"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.70142","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:09:17Z","timestamp":1776096557000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.70142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/1346-8138.70142"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.70142","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"2025-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}